SubscribeLogin
Published

AbelZeta Presents Preclinical Data from Study of C-CAR168 for the Treatment of Autoimmune Diseases at ACR Convergence 2024 - PressReach

Summary by pressreach.com
Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy targeting LN and SLE ROCKVILLE, Md., Nov. 16, 2024 /PRNewswire/ — AbelZeta Pharma, Inc. (“AbelZeta” or the “Company”), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced that preclinical data from its C-CAR168 study has been presented as a podium presentation at the Ameri…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Rockville, MarylandRockville, Maryland
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal